Skip to main content
Fig. 8 | The Journal of Headache and Pain

Fig. 8

From: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Fig. 8

Mean change in disability in the DB period and the OLE as measured by a HIT-6 and b MIDAS (mITT).a,b BL, baseline; DB, double-blind; OLE, open-label extension; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment; mITT, modified intent-to-treat. aAll patients in the OLE received fremanezumab 225 mg monthly

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us